Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sugen (SUGN) -- Ignore unavailable to you. Want to Upgrade?

To: gao seng who wrote (468)	6/12/1999 11:09:00 AM
From: Mike K	Respond to of 550

gao seng; Thanks for posting the article. I'm a multiple myeloma patient who is currently involved in a gene therapy trial using IL-12. 500 ml of my bone marrow has been genetically engineered using an adenovirus, Il-12 and CD-80. This vaccine is being given back to me sub-cutaneously over the next 2 months, at 2 week intervals. Early indications are looking good with a measurable immune response. This is a phase 1 clinical trial being conducted at the University of Toronto / Princess Margaret Hospital. Many trials to-date have involved patients with advanced disease. In my case, I have early stage disease and have not had any form of chemotherapy. Cheers, Mike